Hormonal
GLP-1 receptor ligands reduce cardiovascular mortality and major adverse cardiovascular events in patients with type 2 diabetes, with efficacy varying by specific drug half-life and homology to native GLP-1.
If you have type 2 diabetes and cardiovascular risk, GLP-1 receptor ligands like semaglutide or liraglutide can significantly reduce your risk of heart-related death and events. However, not all GLP-1 drugs offer this specific heart protection; shorter-acting versions may not provide the same benefit. Consult your doctor to ensure you are prescribed a GLP-1 agent with proven cardiovascular outcomes.
Ultimately, clinical trials such as these have confirmed that, similar to sodium glucose co-transporters 2 (SGLT2) inhibitors, GLP-1 mimetics have established CVD benefits in diabetes... a more recent meta-analysis of all these trials confirmed the beneficial actions of GLP-1 mimetics through a 13% relative risk reduction in CVD mortality... However, this CVD benefit may be GLP-1 mimetic specific, given that other trials using GLP-1 mimetics with shorter half-lives and lower homology to native GLP-1, such as lixisenatide (ELIXSA) or exenatide (EXSCEL), failed to show a significant CVD benefit.
Why this rating
Based on multiple large-scale cardiovascular outcome trials (SUSTAIN-6, LEADER, ELIXSA, EXSCEL) and a meta-analysis cited in the text.
Source
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Neil Tanday et al. · British Journal of Pharmacology · 2021
DOI 10.1111/bph.15485
More from this paper
- GLP-1 receptor activation suppresses glucagon secretion primarily through an indirect mechanism involving somatostatin release from delta-cells, rather than direct action on alpha-cells.Good
- GLP-1 receptor ligands improve bone health and reduce fracture risk in type 2 diabetes, with clinical outcomes varying by specific agent.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →